The basic strategy for Yang Zijiang Pharmaceutical Group to invest in Beijing is: devoting itself to drug research and development, focusing on making use of the superior industrial research and development conditions of Life Park and the talents and scientific research advantages of Beijing as an international metropolis, directly connecting with the most advanced international medical technology, strengthening cooperation with domestic and foreign scientific research institutions, and striving to achieve a breakthrough in independent intellectual property rights of drug research and development. The Institute of Pharmacology has full-time new drug researchers 10, including doctors, masters and undergraduates. The researchers all graduated from famous pharmaceutical universities and are fully capable of developing various new drugs. Referring to international standards, the company has established an efficient operation mechanism and research and development system. In terms of experimental instruments, the company has advanced instruments at home and abroad, such as high performance liquid chromatograph, gas chromatograph, ultraviolet spectrophotometer, digital melting point instrument, particle analyzer, pulverizer, drug dissolution instrument, tablet press, granulator, biochemical incubator, microcomputer constant temperature and humidity box, vacuum drying box, optical rotation tester and other instruments. The laboratories such as pharmaceutical chemistry synthesis room, pharmaceutical preparation room, analysis and testing room and physical and chemical laboratory have been established. Established a complete set of institutional setup and staffing, including new drug approval, drug synthesis, analysis and testing, preparation research and new drug approval. Relying on the production workshop of Haiyan Pharmaceutical Co., Ltd., the product was piloted.
In order to master the latest information of drug R&D and cultivate talents, the company has established long-term cooperation in scientific research and training with many famous universities in China, such as Beijing Academy of Military Medical Sciences and Medical Research Institute of Peking Union Medical College. In terms of international communication and cooperation, the company and Dr. Du Shengyan (Ph.D., American Pathology, currently associate professor of neurology at Indiana University, researcher of Alzheimer's Research Center of Indiana University, researcher of Aging and Geriatrics Research Center of Indiana University) * * * jointly established a Sino-foreign cooperative laboratory to jointly develop a new class of drug C- compound for treating coronary heart disease. At present, the pharmacodynamic research of compound C has been completed, and the patent of compound C has been applied in the world and China.